Viking Therapeutics, Inc. VKTX

The business

Viking Therapeutics sells nothing. It is a clinical-stage company with one drug that matters, VK2735, aimed at the largest new market in medicine. VK2735 comes two ways, a weekly injection and a daily pill, and both work the same way as Lilly's Zepbound and Novo's Wegovy, switching on two gut-hormone receptors, GLP-1 and GIP, that tell the body it is full (10-Q, filed 2026-07-29). The injection is the lead, moving through late-stage trials. The pill sits a step behind and is the bigger prize, because an oral obesity drug that actually works is something only Lilly has demonstrated to date based on publicly available data. The mechanism itself is proven and stated in the filing, which is both comfort and threat: comfort because it is de-risked, threat because the field is now crowded with giants. The pivotal weight-loss numbers that will settle the stock are not in this run's evidence, and with no literature search available I found no primary published source to cite for them. Everything Viking is worth rides on those two molecules clearing their trials and then being launched or bought. There is no second act on the shelf.